IP Library Granted Patent US 10,772,881
Granted Patent B2
US 10,772,881 · App. 16/258,060 · Granted Sep 15, 2020

Quinolines that modulate SERCA and their use for treating disease

Inventor: Russell Dahl (Saint John, IN)
A61K31/47A61K31/4709A61K31/502A61P3/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,772,881
App. No.
16/258,060
Granted
Sep 15, 2020
Kind
B2
Abstract

Provided herein are quinolines, e.g., a compound of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes. Also provided herein are methods of their use for modulating the activity of a sarcoplasmic/endoplasmic reticulum C 2+ ATPase.

Claims (10)

1. A method for activating the sarcoplasmic/endoplasmic reticulum calcium ATP-ase (SERCA) in a subject with Alzheimer's disease or Parkinson's disease comprising administering to the subject an effective amount of the compound selected from the group consisting of:

and isotopic variants thereof; and pharmaceutically acceptable salts, solvates, and hydrates thereof.

2. A method for treating, or ameliorating one or more symptoms of diabetes in a subject in need thereof comprising administering to the subject an effective amount of the compound selected from the group consisting of:

and isotopic variants thereof; and pharmaceutically acceptable salts, solvates, and hydrates thereof.

3. The method of claim 2 , wherein the diabetes is type 1.

4. The method of claim 2 , wherein the diabetes is type 2.

5. The method of claim 1 , wherein the C 2+ concentration of an ER is increased.

6. The method of claim 1 , wherein the C 2+ dyshomeostasis is corrected.

7. The method of claim 1 , wherein endoplasmic reticulum stress is reduced.

8. The method of any one of claims 1 , 2 , and 3 - 7 , wherein the subject is a human.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2021
From: DAHL, RUSSELL
To: NEURODON CORPORATION
Reel/Frame 057135/0625 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2021
From: DAHL, RUSSELL, DR
To: NEURODON CORPORATION
Reel/Frame 055251/0757 →
Continuity (2)
Continuation In Part 15507228 · Feb 27, 2017
Related Publication 20190151303A1 · May 23, 2019